^
Association details:
| Biomarker: | KRAS exon 2 mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type
Excerpt:
...The colorectal primary tumor or metastatic tumor must be determined to be KRAS (exon 2 at codon 12 and 13; exon 3 at codon 59 and 61; exon 4 at codon 117 and 146) or NRAS (exon 2 at codon 12 and 13; exon 3 at codon 59 and 61; exon 4 at codon 117 and 146) mutation-type....
Trial ID:
Source:
Title:
Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer
Published date:
11/29/2022
Excerpt:
Data from CRC patients for whom RAS mutational status was analyzed...Treatment with bevacizumab (BV) increased significatively mPFS (p=0.036) and mOS (p=0.019) of the entire population with a substantial benefit in mOS for G12V mutation (p=0.031)….BV was added in 60.4% (n=84) of 139 patients with an exon 2 mutation and showed a concrete increase in survival with a mOS of 27.2 months (IC 95% 20.7-39.4) versus 18.0 months...
DOI:
https://doi.org/10.3389/fonc.2022.1055019
Source:
Title:
P-79 HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of second-line treatment after anti-EGFR antibody
Published date:
07/04/2021
Excerpt:
In this retrospective analysis, IRIS/Bev in the real world clinical practice was an active and tolerated regimen as second-line treatment after anti-EGFR antibody in patients with mCRC.
Secondary therapy:
irinotecan
DOI:
https://doi.org/10.1016/j.annonc.2021.05.134
